Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study

被引：0
|
作者：
Hartung, H-P [1 ,2 ]
Arnold, D. L. [3 ]
Cohen, J. A. [4 ,5 ]
Coles, A. J. [6 ]
Fox, E. J. [7 ]
Havrdova, E. [8 ]
Selmaj, K. W. [9 ]
Margolin, D. H. [10 ]
Palmer, J. [10 ]
Oyuela, P. [10 ]
Panzara, M. A. [10 ]
Compston, D. A. S. [11 ]
机构：
[1] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany
[2] Univ Dusseldorf, Ctr Neuropsychiat, Dusseldorf, Germany
[3] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[4] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA
[6] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
[7] Univ Texas Med Branch, Round Rock, TX USA
[8] Charles Univ Prague, Dept Neurol, Sch Med 1, Prague, Czech Republic
[9] Med Univ Lodz, Dept Neurol, Lodz, Poland
[10] Genzyme, Cambridge, MA USA
[11] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P043
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [21] Disability outcomes for alemtuzumab in RRMS patients who relapsed on prior therapy: CARE-MS II
    Hartung, H. P.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, A.
    JOURNAL OF NEUROLOGY, 2012, 259 : S47 - S48
  • [22] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS-II): subgroup analyses by previous DMT use
    Freedman, M. S.
    Arnold, D. L.
    Cohen, J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Vallee, M.
    Margolin, D. H.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 199 - 200
  • [23] Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study
    Soelberg-Sorensen, Per
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Fox, Edward
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Miller, Tamara
    Twyman, Cary
    Lake, Stephen
    Margolin, David
    Richards, Susan
    Sung, Crystal
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [24] Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
    Coles, Alasdair J.
    NEUROLOGY, 2018, 91 (12) : 571 - 572
  • [25] Alemtuzumab Improves Brain MRI Outcomes in Patients With Active Relapsing-Remitting Multiple Sclerosis: 3-Year Follow-up of the CARE-MS Studies
    Arnold, Douglas
    Cohen, Jeffrey
    Barkhof, Frederik
    Selmaj, Krzysztof
    Margolin, David
    Palmer, Jeffrey
    Fox, Edward
    NEUROLOGY, 2014, 83 (02) : E35 - E36
  • [26] Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
    Avasarala, Jagannadha
    NEUROLOGY, 2018, 91 (12) : 570 - 570
  • [27] Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes
    Krieger, S.
    Freedman, M. S.
    Moreau, T.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 573 - 573
  • [28] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 683 - 683
  • [29] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    JOURNAL OF NEUROLOGY, 2014, 261 : S442 - S443
  • [30] Patients Who Had Highly Active RRMS and an Inadequate Response to Prior Therapy Demonstrated Durable Efficacy with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study
    Singer, Barry
    Krieger, Stephen
    Berkovich, Regina
    Freedman, Mark
    Lycke, Jan
    Margolin, David
    Kasten, Linda
    Havrdova, Eva
    NEUROLOGY, 2016, 86
12345